Alice L Yu

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
    Alice L Yu
    University of California, San Diego, and Moores Cancer Center, San Diego, CA 92103 8447, USA
    N Engl J Med 363:1324-34. 2010
  2. ncbi The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines
    Ayse Batova
    Division of Pediatric Hematology/Oncology, Department of Pediatrics, Medical Center, University of California-San Diego, 200 West Arbor Drive, San Diego, CA 92103-8447, USA
    Blood 100:3319-24. 2002
  3. ncbi Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs
    H Elizabeth Broome
    University of California, San Diego Medical Center, 200 West Arbor Drive, Mail Code 8320, San Diego, CA 92103, USA
    Leuk Res 26:311-6. 2002
  4. ncbi The synthetic caged garcinia xanthone cluvenone induces cell stress and apoptosis and has immune modulatory activity
    Ayse Batova
    Department of Chemistry and Biochemistry, University of California, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Mol Cancer Ther 9:2869-78. 2010
  5. ncbi Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
    Linda S Sorkin
    Department of Anesthesiology, University of California, San Diego School of Medicine, La Jolla, CA 92093, USA
    Pain 149:135-42. 2010
  6. ncbi Synthesis and evaluation of caged Garcinia xanthones
    Ayse Batova
    Department of Pediatrics Hematology Oncology, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103 8447, USA
    Org Biomol Chem 5:494-500. 2007
  7. ncbi 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner
    Mitchell B Diccianni
    Dept of Pediatrics Hematology Oncology, University of California, San Diego, Medical Center, 200 W Arbor Dr, San Diego, CA 92103 8447, USA
    J Exp Ther Oncol 4:223-37. 2004
  8. ncbi Promising therapeutic targets in neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, UCSF Helen Diller Family Comprehensive Cancer Center, and UCSF Benioff Children s Hospital, UCSF Medical Center, University of California, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 18:2740-53. 2012
  9. ncbi Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma
    Sigrun Gebauer
    Division of Pediatric Hematology/Oncology, UCSD Medical Center, 200 West Arbor Drive, San Diego, CA 92103-8447, USA
    Genes Chromosomes Cancer 41:297-308. 2004
  10. ncbi EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine
    Ayse Batova
    Department of Pediatrics/Hematology-Oncology, University of California San Diego, San Diego, CA 92103-8447, USA
    Blood 107:898-903. 2006

Detail Information

Publications10

  1. ncbi Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
    Alice L Yu
    University of California, San Diego, and Moores Cancer Center, San Diego, CA 92103 8447, USA
    N Engl J Med 363:1324-34. 2010
    ..We conducted a study to determine whether adding ch14.18, GM-CSF, and interleukin-2 to standard isotretinoin therapy after intensive multimodal therapy would improve outcomes in high-risk neuroblastoma...
  2. ncbi The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug-resistant primary leukemia and cancer cell lines
    Ayse Batova
    Division of Pediatric Hematology/Oncology, Department of Pediatrics, Medical Center, University of California-San Diego, 200 West Arbor Drive, San Diego, CA 92103-8447, USA
    Blood 100:3319-24. 2002
    ..Collectively, our results suggest that AN-9 is a selective agent for hematopoietic malignancies that can circumvent the mechanisms of chemoresistance limiting most conventional chemotherapy...
  3. ncbi Inhibition of Bcl-xL expression sensitizes T-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs
    H Elizabeth Broome
    University of California, San Diego Medical Center, 200 West Arbor Drive, Mail Code 8320, San Diego, CA 92103, USA
    Leuk Res 26:311-6. 2002
    ..These findings indicate that bcl-x antisense has cytotoxic activity and increases chemotherapy-induced cell death in CEM cells, a model for T-ALL...
  4. ncbi The synthetic caged garcinia xanthone cluvenone induces cell stress and apoptosis and has immune modulatory activity
    Ayse Batova
    Department of Chemistry and Biochemistry, University of California, 9500 Gilman Drive, La Jolla, CA 92093, USA
    Mol Cancer Ther 9:2869-78. 2010
    ..The current work highlights the potential of cluvenone as a chemotherapeutic agent and provides support for further investigation of these intriguing molecules with regard to mechanism and targets...
  5. ncbi Anti-GD(2) with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
    Linda S Sorkin
    Department of Anesthesiology, University of California, San Diego School of Medicine, La Jolla, CA 92093, USA
    Pain 149:135-42. 2010
    ....
  6. ncbi Synthesis and evaluation of caged Garcinia xanthones
    Ayse Batova
    Department of Pediatrics Hematology Oncology, University of California, San Diego, 200 West Arbor Drive, San Diego, CA 92103 8447, USA
    Org Biomol Chem 5:494-500. 2007
    ....
  7. ncbi 3-amino thioacridone inhibits DNA synthesis and induce DNA damage in T-cell acute lymphoblastic leukemia (T-ALL) in a p16-dependent manner
    Mitchell B Diccianni
    Dept of Pediatrics Hematology Oncology, University of California, San Diego, Medical Center, 200 W Arbor Dr, San Diego, CA 92103 8447, USA
    J Exp Ther Oncol 4:223-37. 2004
    ..We conclude that 3-ATA efficacy can be predicted by p16 status in T-ALL, but the mechanism of action may be distinct from their in vitro ability to regulate CDK4 kinase activity..
  8. ncbi Promising therapeutic targets in neuroblastoma
    Katherine K Matthay
    Department of Pediatrics, UCSF Helen Diller Family Comprehensive Cancer Center, and UCSF Benioff Children s Hospital, UCSF Medical Center, University of California, San Francisco, CA 94143 0106, USA
    Clin Cancer Res 18:2740-53. 2012
    ..Further clinical development of targeted treatments offers new hope for children with neuroblastoma...
  9. ncbi Expression profiles and clinical relationships of ID2, CDKN1B, and CDKN2A in primary neuroblastoma
    Sigrun Gebauer
    Division of Pediatric Hematology/Oncology, UCSD Medical Center, 200 West Arbor Drive, San Diego, CA 92103-8447, USA
    Genes Chromosomes Cancer 41:297-308. 2004
    ..Finally, the loss of CDKN1B in advanced-stage neuroblastoma suggests this protein may play a role in the neuroblastoma disease process...
  10. ncbi EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine
    Ayse Batova
    Department of Pediatrics/Hematology-Oncology, University of California San Diego, San Diego, CA 92103-8447, USA
    Blood 107:898-903. 2006
    ..Collectively, these data indicate that EFA is an effective agent for salvaging MTAP+ cells from L-alanosine toxicity and is superior to MTA due to lower cytotoxicity...